Chemical Component Summary

FormulaC16 H38 N2
Molecular Weight258.49

Chemical Details

Formal Charge2
Atom Count56
Chiral Atom Count0
Chiral Atomsn/a
Bond Count55
Aromatic Bond Count0
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB01245 Different stereochemistry
DescriptionDecamethonium is a short acting depolarizing muscle relaxant or neuromuscular blocking agent, and is used in anesthesia to induce paralysis. It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.
  • Decamethonium
  • Decamethonum
  • Decamethylenebis(trimethylammonium)
  • N,N,N,N',n',n'-hexamethyl-1,10-decanediaminium
SaltsDecamethonium bromide
Brand NamesSyncurine
Affected OrganismHumans and other mammals
IndicationFor use as a skeletal muscle relaxant
PharmacologyDecamethonium acts as a depolarizing muscle relaxant or neuromuscular blocking agent. It acts as an agonist of nicotinic acetycholine receptors in the motor endplate and causes depolarization. This class of drugs has its effect at the neuromuscular junction by preventing the effects of acetylcholine. Normally, when a nerve stimulus acts to contract a muscle, it releases acetylcholine. The binding of this acetylcholine to receptors causes the muscle to contract. Muscle relaxants play an important role in anesthesia even though they don't provide any pain relief or produce unconsciousness.
Mechanism of actionBinds to the nicotinic acetycholine receptors (by virtue of its similarity to acetylcholine) in the motor endplate and blocks access to the receptors. In the process of binding, the receptor is actually activated - causing a process known as depolarization. Since it is not degraded in the neuromuscular junction, the depolarized membrance remains depolarized and unresponsive to any other impulse, causing muscle paralysis.
  • Amines
  • Ammonium Compounds
  • Bis-Trimethylammonium Compounds
  • Chemical Actions and Uses
  • Cholinesterase Inhibitors
CAS number156-74-1
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682